Sanofi is Awarded the Supply of Influenza Vaccines in the Balearic Islands

The Balearic Islands prepares its health system to face the next common flu seasons. The Ministry of Health and Consumption of the autonomous community has awarded Sanofi the supply of flu vaccines for $5 million (€4.4 million). The contract has a two-year term, plus a two-year extension option, until the 2024 winter vaccination campaign, according to the community’s contractor profile.

Each year 304,800 doses will be dispensed. The award is part of the framework agreement for the selection of suppliers of seasonal flu vaccines for certain contracting bodies of the National Institute of Health Management (Ingesa) and the cities of Ceuta and Melilla and several autonomous communities.

Find more about Sanofi and read the latest finance news with the Born2Invest mobile app. Don’t waste your time scrolling the internet, our team of seasoned journalists brings you the most important market updates so you don’t miss anything.

Sanofi has snatched the contract from Mylan Pharmaceuticals

References indicate that, during the 2020 vaccination campaign, 223,585 doses were consumed. This year and for the second consecutive winter, the situation derived from the pandemic “has increased the need to obtain good coverage, so it is advisable to have more doses with the aim of expanding the target groups,” the administration has underlined in the contract justification report.

The contract has been awarded at the proposal of the Balearic Ministry of Health and Consumption, by means of the urgent procedure. Sanofi’s vaccines have been produced from embryonated viruses, fractionated viruses, or by means of surface antigens. The price per dose will be $10.2 (€8.79).

The other candidate company, Mylan Pharmaceuticals, had made a bid of $10.8 (€9.3) per dose. The planned award conditions had awarded fifty points to the bid price, out of a total of one hundred.

Sanofi, Mylan, and Seqirus were awarded in October the supply of common flu vaccines nationwide for a total of $321 million (€277 million)

The remaining criteria were listed as “other” and covered the remaining points. In this case, the volume of injectables and the type of vaccines used by each company were included.

At the beginning of October, Sanofi, Mylan, and Seqirus were awarded the supply of common flu vaccines nationwide for a total of $321 million (€277 million). The French company was awarded half of the first lot for (€9.5 million), number 4 and number 6, both for $29 million (€25 million). Mylan, for its part, won the other half of lot 1 for $11 million (€9.5 million).

Sanofi is a French pharmaceutical company, headquartered in Paris, with a diversified product portfolio. The company produces and markets medicines, consumer healthcare products, generics, vaccines, and also animal health-oriented drugs. The company is present in around 100 countries and employs more than 100,000 people.

__

(Featured image by Mufid Majnun via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.